OR WAIT null SECS
August 10, 2016
FDA issued a warning letter to contract testing laboratory, Adamson Analytical Laboratories, for CGMP violations.
August 03, 2016
Xiamen Origin Biotech Co., Ltd, was cited, not only for inadequate quality management, but for falsifying information on certificates of analysis, having fictional employees sign CoAs, and having employees lie to inspectors.
July 22, 2016
The company announced that its facilities and laboratories have completed FDA pre-qualification inspection.
July 21, 2016
GenPak Solutions is cited by FDA for cGMP violations at its Hilliard, Ohio facility.
July 19, 2016
FDA issued a warning letter to the Worthing, UK facility for cross contamination and microbial contamination cGMP violations.
July 06, 2016
FDA cited Guangzhou Haishi Biological Technology Co., Ltd. with CGMP violations.
June 15, 2016
The agency cited a Memphis drug compounder for misbranded drugs and a lack of appropriate sterile processes.
The issues cites the Taiwan facility with violations of current good manufacturing practice regulations.
FDA cited a Las Vegas compounding pharmacy for sterility violations.
FDA sent a warning letter to The Compounding Pharmacy of America for deficiencies in sterile manufacturing.